Floatz Rating
B63/100
Confidence
Indicative
Sponsor
Mirati Therapeutics Inc.
Modality
monoclonal_antibody
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
61High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07415031CT.gov A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies | — | Recruiting | — | — | — |
NCT07300150CT.gov A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT07030959CT.gov Study of AUBE00 in Patients With Solid Tumors | — | Recruiting | — | — | — |
NCT06818812CT.gov A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | — | Active Not Recruiting | — | — | — |
NCT06978400CT.gov A Study of Dabrafenib Plus Cetuximab/Panitumumab With FOLFOX in the First Line of Therapy in People With Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
NCT06967155CT.gov A Study of Irinotecan With Dabrafenib Plus Trametinib and Anti-EGFR in the Second Line of Therapy in People With Metastatic Colorectal Cancer | — | Active Not Recruiting | — | — | — |
NCT06551142CT.gov A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD) | — | Recruiting | — | — | — |
NCT06227377CT.gov QTX3034 in Patients With KRAS G12D Mutation | — | Recruiting | — | — | — |
NCT06179160CT.gov A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | — | Recruiting | — | — | — |
NCT05836324CT.gov A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | — | Recruiting | — | — | — |
Show 27 more trialsShow fewer
NCT05786924CT.gov Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies | — | Recruiting | — | — | — |
NCT05668585CT.gov A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors | — | Completed | — | — | — |
NCT05584670CT.gov A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT05203172CT.gov The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials | — | Recruiting | — | — | — |
NCT05382559CT.gov A Study of ASP3082 in Adults With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT04717375CT.gov Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT04800822CT.gov PF-07284892 in Participants With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT04607421CT.gov A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer | — | Active Not Recruiting | — | — | — |
NCT03783403CT.gov A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic Cancers | — | Terminated | — | — | — |
NCT03693612CT.gov GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors | — | Completed | — | — | — |
NCT03552406CT.gov Study of ISU104, Targeting ERBB3 in Patients With Advanced Solid Tumors | — | Unknown | — | — | — |
NCT02953782CT.gov Study of Magrolimab (Hu5F9-G4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer | — | Completed | — | — | — |
NCT02675946CT.gov CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596) | — | Unknown | — | — | — |
NCT02627274CT.gov A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C) | — | Completed | — | — | — |
NCT02020577CT.gov Trial of Afatinib (BIBW 2992) + Cetuximab in Advanced Solid Tumours | — | Completed | — | — | — |
NCT01973868CT.gov Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination | — | Completed | — | — | — |
NCT01787500CT.gov Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery | — | Completed | — | — | — |
NCT01482377CT.gov A Study of RO5479599 Alone or in Combination With Cetuximab or Erlotinib in Participants With Metastatic and/or Locally Advanced Malignant Human Epidermal Growth Factor Receptor (HER3) Expressing Solid Tumors of Epithelial Cell Origin | — | Completed | — | — | — |
NCT01063075CT.gov A Study in Advanced Solid Tumors | — | Completed | — | — | — |
NCT01099358CT.gov Study in Advanced Solid Tumors | — | Completed | — | — | — |
NCT01166035CT.gov Lenalidomide and Cetuximab in Patients With Advanced Solid Tumors | — | Unknown | — | — | — |
NCT01031212CT.gov ASA404 in Combination With Carboplatin/Paclitaxel/Cetuximab in Treating Patients With Refractory Solid Tumors | — | Withdrawn | — | — | — |
NCT00954512CT.gov Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004) | — | Terminated | — | — | — |
NCT00811993CT.gov A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT00598975CT.gov NKTR-102 in Combination With Cetuximab in Patients With Refractory Solid Tumors (Phase 2a) and Metastatic or Locally Advanced Colorectal Cancer (Phase 2b) | — | Completed | — | — | — |
NCT00207077CT.gov Study of Cetuximab in Combination With Tarceva in Patients With Solid Tumors | — | Completed | — | — | — |
NCT00083720CT.gov Erbitux (Cetuximab) Given Alone to Patients With EGFR-Negative Metastatic Colon or Rectal Cancer That is Refractory to Chemotherapy | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cetuximab (this asset) | Mirati Therapeutics Inc. | Approved | B · 63 |
| Panitumumab | Astellas Pharma Inc | P2 | BBB |
| Granulocyte Colony-Stimulating Factor Lenograstim | Sanofi | P4 | BB |
| Dexmedetomidine | Medical College of Wisconsin | P4 | BB |
| Lidocaine | Medical College of Wisconsin | P4 | BB |
| Relatlimab | Bristol-Myers Squibb | P2 | BB |
| Vitamin D | Tanta University | P4 | BB |
| Glycopyrrolate | Medical College of Wisconsin | P4 | BB |
| Dinitrogen Monoxide | Medical College of Wisconsin | P4 | BB |
+42 more in the Neoplasm cohort
Other indications for Cetuximab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Colon Adenocarcinoma | — | P3 | BB · 70 |
| Rectal Carcinoma | — | P2 | BB · 69 |
| Non-Small Cell Lung Carcinoma | — | P3 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cetuximab in Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cetuximab-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →